Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (DFPH) Profit After Tax (2020 - 2025)

Historic Profit After Tax for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to -$16.5 million.

  • Oncology Institute's Profit After Tax fell 242.66% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.3 million, marking a year-over-year increase of 563.11%. This contributed to the annual value of -$64.7 million for FY2024, which is 2215.65% up from last year.
  • Latest data reveals that Oncology Institute reported Profit After Tax of -$16.5 million as of Q3 2025, which was down 242.66% from -$17.0 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Profit After Tax registered a high of $19.3 million during Q1 2022, and its lowest value of -$30.0 million during Q1 2023.
  • Over the past 5 years, Oncology Institute's median Profit After Tax value was -$15.5 million (recorded in 2024), while the average stood at -$11.1 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first soared by 203634.54% in 2022, then plummeted by 55142.11% in 2023.
  • Oncology Institute's Profit After Tax (Quarter) stood at -$10.2 million in 2021, then decreased by 8.38% to -$11.0 million in 2022, then plummeted by 70.38% to -$18.8 million in 2023, then rose by 29.71% to -$13.2 million in 2024, then fell by 25.2% to -$16.5 million in 2025.
  • Its Profit After Tax was -$16.5 million in Q3 2025, compared to -$17.0 million in Q2 2025 and -$19.6 million in Q1 2025.